The DECLARE, CANVAS and EMPA-REG CV outcomes trials assessing the SGLT2 inhibitors dapagliflozin (Farxiga, AstraZeneca), canagliflozin (Invokana, Janssen) and empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly), respectively, all showed CV and renal benefit in adults with type 2 diabetes with established CVD, DeFronzo said
While these strategies remain experimental, they offer hope for patients with recurrent or refractory disease (Plotkin & Blakeley, 2022)
[DOI] [PMC free article] [PubMed] [Google Scholar] 67.Satoh Y, Kawai H, Kudo N, Kawashima Y, Mitsumoto A
In Part A of the study, five cohorts of participants received a single s.c
Lipo Injections can help support liver health, promote fat metabolism, and reduce the risk of fatty liver disease